The Inhibitory Effect of Human Beta-defensin-3 on Candida Glabrata Isolated from Patients with Candidiasis



Inthanachai, Thananya, Thammahong, Arsa, Edwards, Steven W ORCID: 0000-0002-7074-0552, Virakul, Sita, Kiatsurayanon, Chanisa and Chiewchengchol, Direkrit ORCID: 0000-0003-1824-7012
(2021) The Inhibitory Effect of Human Beta-defensin-3 on Candida Glabrata Isolated from Patients with Candidiasis. IMMUNOLOGICAL INVESTIGATIONS, 50 (1). pp. 80-91.

[img] Text
Revised Manuscript R1.pdf - Author Accepted Manuscript

Download (689kB) | Preview

Abstract

<i>Candida glabrata</i> is a common non-<i>albicans Candida</i> species found in patients with candidiasis and it sometimes develops antifungal resistance. Human beta-defensin-3 (hBD-3) is an antimicrobial peptide of immune system active against various types of microbes including <i>Candida spp</i>. This study investigated antifungal activity of hBD-3 and its synergistic effect with a first-line antifungal agent on <i>C. glabrata</i> clinical isolates. <i>Candida spp</i>. were characterised in patients with candidiasis. The antifungal activities of hBD-3 and fluconazole against <i>C. glabrata</i> were evaluated using Broth microdilution assay. The synergistic activity of these two agents was determined by checkerboard microdilution and time-killing assays. The cytotoxicity of hBD-3 was evaluated using LDH-cytotoxicity colorimetric assay. Of 307 episodes from 254 patients diagnosed with candidiasis, <i>C. glabrata</i> was found in 21 clinical isolates. Antifungal susceptibility tests of <i>C. glabrata</i> were performed, fluconazole demonstrated an inhibitory effect at concentrations of 0.25-8 μg/ml, but one antifungal resistant strain was identified (>64 μg/ml). hBD-3 showed an inhibitory effect against all selected strains at concentrations of 50-75 μg/ml and exhibited a synergistic effect with fluconazole at the fractional inhibitory concentration index (FICI) of 0.25-0.50. A concentration of 25 μg/ml of hBD-3 alone showed no cytotoxicity but synergistic activity was seen with fluconazole. In conclusion, hBD-3 has antifungal activity against <i>C. glabrata</i> and synergistic effects with fluconazole at concentrations that alone, have no cytotoxicity. hBD-3 could be used as an adjunctive therapy with first-line antifungal agents for patients with <i>C. glabrata</i> infection particularly those infected with fluconazole-resistant strains.

Item Type: Article
Uncontrolled Keywords: Human beta-defensin, candida glabrata, candidiasis
Depositing User: Symplectic Admin
Date Deposited: 28 Apr 2020 09:38
Last Modified: 18 Jan 2023 23:53
DOI: 10.1080/08820139.2020.1755307
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3084988